Skip to content
EntityQ425911· pop 14· linked from 116 articles

Also known as N-butyl-1-deoxynojirimycin, NB-DNJ, Zavesca®, SC-48334, n-Butyl deoxynojirimycin, N-Butylmoranoline, N-(n-Butyl)deoxynojirimycin, Butyldeoxynojirimycin

Miglustat, sold under the brand name Zavesca among others, is a medication used to treat type I Gaucher disease and Pompe disease.

Key facts

Drug.ChEMBL
1029
Drug.verifiedrevid
462252392
Drug.image
Miglustat.svg
Drug.image_class
skin-invert-image
Drug.width
250
Drug.tradename
Zavesca, Brazaves, Opfolda
Drug.MedlinePlus
a604015
Drug.licence_EU
yes
Drug.DailyMedID
Miglustat
Drug.licence_US
Miglustat
Drug.pregnancy_AU
D
Drug.routes_of_administration
By mouth
Drug.ATC_prefix
A16
Drug.ATC_suffix
AX06
Drug.legal_AU
S4
Drug.legal_UK
POM
Drug.legal_US
Rx-only
Drug.legal_EU
Rx-only

via Wikipedia infobox

Wikidata facts

Mass
219.147
Show 7 more facts
chemical formula
C₁₀H₂₁NO₄
isomeric SMILES
CCCCN1C[C@@H]([C@H]([C@@H]([C@H]1CO)O)O)O
canonical SMILES
CCCCN1CC(C(C(C1CO)O)O)O
World Health Organisation international non-proprietary name
miglustat
defined daily dose
0.3
stylized name
migLUstat
Commons category
Miglustat
Sources (7)

via Wikidata · CC0

~5 min read

Article

9 sections
Contents
  • Medical uses
  • Contraindications
  • Adverse effects
  • Mechanism of action
  • Chemistry
  • Society and culture
  • Legal status
  • Research
  • References

Miglustat, sold under the brand name Zavesca among others, is a medication used to treat type I Gaucher disease and Pompe disease.

It was approved for medical use in the European Union in November 2002, and for medical use in the United States in July 2003.

Connections

Categories